Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Nov 2;6(6):zrac141.
doi: 10.1093/bjsopen/zrac141.

Resectability of bilobar liver tumours after simultaneous portal and hepatic vein embolization versus portal vein embolization alone: meta-analysis

Remon Korenblik  1   2 , Jasper F J A van Zon  1 , Bram Olij  1   2   3 , Jan Heil  4 , Maxime J L Dewulf  1 , Ulf P Neumann  1   3 , Steven W M Olde Damink  1   3   5 , Christoph A Binkert  6 , Erik Schadde  7   8 , Christiaan van der Leij  9 , Ronald M van Dam  1   2   3 ; DRAGON Trials Collaborative
Collaborators, Affiliations
Meta-Analysis

Resectability of bilobar liver tumours after simultaneous portal and hepatic vein embolization versus portal vein embolization alone: meta-analysis

Remon Korenblik et al. BJS Open. .

Abstract

Background: Many patients with bi-lobar liver tumours are not eligible for liver resection due to an insufficient future liver remnant (FLR). To reduce the risk of posthepatectomy liver failure and the primary cause of death, regenerative procedures intent to increase the FLR before surgery. The aim of this systematic review is to provide an overview of the available literature and outcomes on the effectiveness of simultaneous portal and hepatic vein embolization (PVE/HVE) versus portal vein embolization (PVE) alone.

Methods: A systematic literature search was conducted in PubMed, Web of Science, and Embase up to September 2022. The primary outcome was resectability and the secondary outcome was the FLR volume increase.

Results: Eight studies comparing PVE/HVE with PVE and six retrospective PVE/HVE case series were included. Pooled resectability within the comparative studies was 75 per cent in the PVE group (n = 252) versus 87 per cent in the PVE/HVE group (n = 166, OR 1.92 (95% c.i., 1.13-3.25)) favouring PVE/HVE (P = 0.015). After PVE, FLR hypertrophy between 12 per cent and 48 per cent (after a median of 21-30 days) was observed, whereas growth between 36 per cent and 67 per cent was reported after PVE/HVE (after a median of 17-31 days). In the comparative studies, 90-day primary cause of death was similar between groups (2.5 per cent after PVE versus 2.2 per cent after PVE/HVE), but a higher 90-day primary cause of death was reported in single-arm PVE/HVE cohort studies (6.9 per cent, 12 of 175 patients).

Conclusion: Based on moderate/weak evidence, PVE/HVE seems to increase resectability of bi-lobar liver tumours with a comparable safety profile. Additionally, PVE/HVE resulted in faster and more pronounced hypertrophy compared with PVE alone.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of the applied search strategy, study selection/inclusion, and reason for exclusion
Figure 2.
Figure 2.
Forest plot of calculated ORs (95% c.i.) for resectability in comparative studies PVE, portal vein embolization; PVE/HVE, simultaneous PVE and hepatic vein embolization.
See this image and copyright information in PMC

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–2917 - PubMed
    1. Jemal A, Bray F, Ferlay J. Global cancer statistics: 2011. CA Cancer J Clin 1999;49:33–64 - PubMed
    1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, The ESMO Guidelines Working Group . Metastatic colorectal cancer: eSMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(Suppl 3):iii1–iii9 - PubMed
    1. Cescon M, Vetrone G, Grazi GL, Ramacciato G, Ercolani G, Ravaioli Met al. . Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg 2009;249:995–1002 - PubMed
    1. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little Set al. . Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397–406 - PMC - PubMed

Publication types